

Clinical Oversight Review Board (CORB) Criteria for Prescribing Mogamulizumab-kpkc (Poteligeo)

Non-Formulary **mogamulizumab-kpkc (Poteligeo)** requires a clinical review. Appropriateness of therapy will be based on the following criteria:

Initiation (new start) criteria or criteria for current OR new Kaiser Permanente members already taking the medication who have not been reviewed previously:

Non-formulary **mogamulizumab-kpkc (Poteligeo)** will be covered on the prescription drug benefit when the following criteria are met:

- Prescribed by Hematology/ Oncology provider
- Patient is at least 18 years of age
- Diagnosis of relapsed or refractory mycosis fungoides or Sézary syndrome
- Patient has lack of response at least 1 prior lines of systemic therapy